Top Markets
Coin of the day
NuCana plc NuCana plc

NuCana plc

NCNA
주식 순위 #32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
주가
$1.56
시가총액
$9.44M
변동 (1일)
-2.20%
변동 (1년)
-58.31%
국가
GB
거래 NuCana plc (NCNA)

카테고리

NuCana plc (NCNA)의 주식 분할 이력
NuCana plc 주식 (심볼: NCNA)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 17, 2026에 발생했습니다.
Aug 17, 2026 이전에 매수한 NCNA 주식 1주는 현재 0주의 NCNA 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE